doi: 10.3389/fphar.2025.1438318 Received 31 May 2024 Accepted 11 April 2025 Published 15 May 2025 Volume 16 - 2025 Edited by Bernd Rosenkranz, Fundisa African Academy of Medicines Development, South Africa Reviewed by C
Semaglutide might reduce the risk of Alzheimers disease Researchers report that patients treated with semaglutide have achieved a significantly lower risk of developing Alzheimers disease compared to those exposed to seven other anti-diabetic medications, including other GLP-1R-targeting drugs
After 12 months of treatment, people who took: Tirzepatide lost an average of 15% of their body weight Semaglutide lost an average of 8% of their body weight While the potential weight loss outcomes with both drugs are promising, these medications arent a cure-all
For example, a 200lb person might expect to lose approximately 30 pounds over a period of 3 to 6 months on a weight management program with semaglutide, Omaha
Step 2: Warm the medication